Background
Alzheimer's disease is the most common form of dementia and is a major contributor to morbidity and mortality in older Australians.
Objectives
The aim of this article is to provide an overview of available pharmacological therapies for the symptomatic treatment of Alzheimer's disease.
Discussion
Acetylcholinesterase inhibitors (AChEIs) or memantine may be trialled in people with Alzheimer's disease to delay symptoms of cognitive and functional decline. The choice of pharmacological agent is based on the stage of Alzheimer's disease, tolerability, adverse effect profile, ease of use and cost. People should be monitored for efficacy, side effects and possible treatment discontinuation. Strategies should be used to optimise medication management and adherence. Evidence for other pharmacological therapies is mixed or lacking. Behavioural and psychological symptoms of dementia (BPSD) are common in people with Alzheimer's disease and may respond to symptomatic pharmacological and nonpharmacological treatment.
THERE ARE ABOUT 425,400 Australians living with dementia and this is expected to increase to over one million by 2056. 1, 2 Dementia is the second leading cause of death and the single greatest cause of disability in older Australians. 3 Dementia is estimated to cost Australia more than $15 billion each year. 2 Alzheimer's disease is the most common form of dementia, affecting up to 70% of all people with dementia. 4 Accumulation of beta-amyloid peptide and intracellular tau protein appear to be central to the degenerative changes in Alzheimer's disease. These result in the destruction of neurones, including cholinergic neurones, and a fall in acetylcholine concentration. 5 None of the available medications prevents Alzheimer's disease or modifies its pathology. However, medications may be used in conjunction with nonpharmacological treatments to manage cognition, function and behaviour. This article will focus on pharmacological approaches to managing Alzheimer's disease, with a focus on practice points and common adverse events.
Current pharmacological therapies
Currently, there are two classes of medications used in the treatment of Alzheimer's disease: acetylcholinesterase inhibitors (AChEIs) and memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist. A summary of the dosing schedules, available products and treatment recommendations is reported in Tables 1 and 2 .
Acetylcholinesterase inhibitors
AChEIs decrease the breakdown of acetylcholine, thereby reducing the apparent deficiency of cholinergic neurotransmitter activity. They are indicated for the treatment of mild-tomoderate Alzheimer's disease. To be eligible for a Pharmaceutical Benefit Scheme (PBS) subsidy, the diagnosis must be confirmed by, or made in consultation with, a medical specialist such as a geriatrician, neurologist or psychiatrist. Additionally, the person with Alzheimer's disease must have a Mini-Mental State Examination (MMSE) or standardised MMSE score of ≥10.
Currently available AChEIs include donepezil, galantamine and rivastigmine. A meta-analysis reported that all three AChEIs have similar efficacy and safety. 6 Choice of AChEIs is based on ease of use, tolerability, cost, and clinician and patient preference. Some people who are unresponsive to one AChEI may appear to stabilise or, rarely, improve when switched to another. 7 In particular, people who are unresponsive to selective AChEIs may benefit from switching to a dual AChEbutyrylcholinesterase inhibitor (BuChEI) such as rivastigmine. 
Contraindications and precautions
AChEIs are contraindicated in people with gastrointestinal (GI) or ureteric obstruction, or active peptic ulcer. 9 It is recommended that AChEIs be used Current approaches to the pharmacological treatment of Alzheimer's disease with caution in people with a history of peptic ulcer disease, seizures, heart block, bradyarrhythmias (including sick sinus syndrome), asthma and obstructive pulmonary disease.
The concurrent use of AChEIs with medications with anticholinergic properties should be avoided, given conflicting mechanisms of action and the potential to antagonise therapeutic effects. 10 However, Australian and North American studies published over the past decade suggest that over one-third of AChEI users are co-prescribed an anticholinergic medication, which is often the result of prescribing cascades.
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Other medications that should be used with caution with AChEIs include those that cause bradycardia, as the risk of bradycardia, hypotension and syncope may be increased. 12 Adverse events are mainly GI-related and include nausea, vomiting and diarrhoea. Toxicity is dose-related and usually resolves with time or dose reduction. Dizziness, drowsiness, bradycardia and syncope may also occur, making older adults more prone to falls and fractures. 12 Other common adverse effects (>1%) listed in the Australian medicines handbook include weight loss, anorexia, depression, headache, vivid dreams and muscle cramps. 9, 13 Significant overdose with AChEIs can result in cholinergic crisis, characterised by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions.
Memantine
Memantine is an NMDA receptor antagonist that normalises the glutamatergic system and reduces glutamate-induced neuronal degradation in Alzheimer's disease. 14 Memantine is recommended for people with moderateto-severe Alzheimer's disease who are intolerant of or have a contraindication to AChEIs. 15 Memantine can be used in combination with AChEI therapy; however, memantine is PBS-subsidised only as a stand-alone therapy in people with an MMSE score of 10-14. Memantine is contraindicated in people with a history of seizures. 9 It is generally well tolerated; however, adverse effects include GI upset, confusion, dizziness, drowsiness, headache and agitation. 9 
Monitoring efficacy and follow-up
AChEIs and memantine show modest efficacy in improving cognition and/ or reducing the rate of cognitive and functional decline. 16 A recent metaanalysis of 43 17 A meta-analysis of 30 RCTs found memantine improved cognitive function and behavioural disturbances when compared with placebo. 18 When compared with AChEI monotherapy, the combination of an AChEI and memantine led to modest improvement in cognition and global function at six months in people with advanced Alzheimer's disease. 19 Whether these medications considerably improve long-term outcomes -such as the need for admission to residential aged care, maintaining critical activities of daily living, or quality of life -has not been shown. 20 The response to antidementia medications varies, with up to 30-50% of people showing no benefit, while a smaller proportion (up to 20%) may show a greater than average response. 21 This highlights the importance of individualising treatment decisions on the basis of clinical response and adverse events.
The Clinical practice guidelines for dementia in Australia recommend that before commencing therapy, an electrocardiogram, weight recording and falls risk assessment be conducted. 15 The guidelines suggest that people who have been prescribed an AChEI or memantine should be reviewed shortly after initiation (eg one month) for assessment of adverse events and need for dose titration, and within six months to establish whether a clinically meaningful response to therapy exists. 15 PBS-subsidised continuation beyond six months is dependent on the person having achieved a clinically meaningful response in terms of quality of life, cognition or behavioural symptoms. Cognitive function, caregiver impression of change, sleep, and behavioural and psychological symptoms of dementia (BPSD) should be assessed at each visit. Routine laboratory monitoring is not required for any of the antidementia medications. Table 2 . Summary of pharmacological treatment recommendations in Alzheimer's disease 15, 25 Stage Recommendation
Newly diagnosed mild-to-moderate Alzheimer's disease
Trial an AChEI Donepezil, galantamine or rivastigmine chosen on the basis of ease of use, tolerability, cost, and clinician and patient preference, as efficacy appears to be similar
Moderate-to-severe dementia
Continue AChEI or change to memantine in people who do not tolerate or benefit from a AChEI
Advanced dementia Continue memantine
In some people with advanced dementia it may be beneficial to discontinue administration of medications to maximise quality of life and comfort.
Behavioural and psychological symptoms Antipsychotics
An antipsychotic should only be used if the following conditions are met: 15 • Possible benefits and risks of treatment have been fully discussed with the patient and their family and/or carers. This should include assessment of cerebrovascular risk factors and a discussion about the possible increase in the risk of stroke and adverse effects on cognition.
• Target symptoms have been identified, quantified and documented
• Effects of comorbid conditions, such as depression, have been considered.
• An individual risk-benefit analysis has been undertaken to determine which agent is most suitable.
• Treatment is commenced with a low dose and titrated upwards if necessary.
• The patient is monitored for adverse events, including metabolic syndrome.
• Treatment is discontinued if no effect is seen within one to two weeks.
• If antipsychotics are used, choose an atypical or second-generation antipsychotic.
Treatment options* include:
• risperidone, doses not exceeding 1 mg daily
• olanzapine, start at 2.5 mg daily and titrated up to maximum of 5 mg twice a day
• quetiapine, start at 25 mg at bedtime and titrate up to a maximum of 75 mg twice a day 
Medication management and adherence
Alzheimer's disease is associated with medication management issues and low rates of adherence, with over 30% of people with dementia not taking their medications as intended. 22 Examples of strategies to optimise medication use and adherence in people living with Alzheimer's disease are listed in Box 1.
Discontinuing therapy
The optimal duration of treatment with Alzheimer's disease medications is unclear, and an ongoing and individualised assessment of benefit and adverse events should be used to guide continuation. 23 The recent Evidence-based clinical practice guideline for deprescribing cholinesterase inhibitors and memantine (the Guidelines) was based on a systematic review of international literature and endorsed by the National Health and Medical Research Council (NHMRC). The Guidelines recommend that for people taking an AChEI and/or memantine for longer than 12 months, a trial of discontinuation is considered if cognition and/or function has deteriorated significantly during the previous six months, if there was no benefit observed at any time during therapy, or if the person has severe or advanced dementia in which there is little hope of a meaningful benefit to continued therapy. 24 Other reasons for discontinuation include poor tolerance despite dose reduction or medication switching, comorbidities or non-adherence that make continued use unacceptably risky or futile.
Unless there is an adverse drug reaction that necessitates rapid cessation, or the medication is already at the lowest dose, dosage should be tapered by half every four weeks to the lowest dose available before discontinuation, to minimise risk of dementia symptoms worsening during withdrawal. 24 The medication should generally be re-introduced if a clinical decline occurs. If severe symptoms occur within one week of dose reduction/ cessation, this may indicate a withdrawal event related to discontinuation and the previous dose should be restarted. If symptoms occur within six weeks, this may indicate reccurrence of symptoms that were being managed by AChEI/ memantine and restarting the previous dose may be considered. 24 
Other therapies
Evidence is limited for other pharmacological approaches. These are summarised in Table 3 . 25 
Management of BPSD
BPSD is common in Alzheimer's disease, particularly in the mid-to-late stages, and contributes to admission to residential aged care and caregiver stress. These symptoms include agitation, aggression, hallucinations, delusions, depression, apathy, wandering, disinhibition and sleep disturbances. 26 When a person with Alzheimer's disease develops BPSD, the first step is to identify possible precipitating factors and rule out or treat a medical cause (eg pain or infection) or superimposed delirium. 26 Non-pharmacological interventions should be considered first, because pharmacological treatment for BPSD is not necessarily effective.
Prior to commencing pharmacological therapy, it is important to know which symptoms are being targeted for treatment. Although a drug may be indicated for BPSD management, this does not mean all symptoms are likely to respond equally well to that drug. 27 When treating agitation in people with Alzheimer's disease, the Clinical practice guidelines for dementia in Australia suggest that a selective serotonin reuptake inhibitor (SSRI) may be trialled (the strongest evidence for effectiveness exists for citalopram) if non-pharmacological therapy has failed or is inappropriate. 15 A recent network meta-analysis reported that SSRIs as a class had efficacy for alleviating agitation, but when analysed separately, citalopram was not significantly efficacious. 28 Evaluation of efficacy and the potential for deprescribing should take place after two months. 15 The time to onset of action, importance of adherence, and There is uncertainty about the use of antidepressants in the treatment of depression in Alzheimer's disease. A meta-analysis of six RCTs found no clear evidence to support the efficacy of antidepressants for treating depression in Alzheimer's disease. 29 There are also concerns that they may increase the risk of mortality, although the evidence for this is inconclusive. 30 Despite the uncertainties, the Guidelines recommend that people with Alzheimer's disease who develop major depression and have a pre-existing history of major depression prior to Alzheimer's disease development should receive usual antidepressant therapy. 15 Antipsychotics should generally be avoided in people with Alzheimer's disease because of the increased risk of stroke, death and cognitive worsening. 31 However, the Guidelines suggest patients may trial an antipsychotic if they have severe BPSD (ie psychosis and/or agitation or aggression) that results in considerable distress to themselves or others. 15 Atypical or second-generation antipsychotics with less tendency to cause extrapyramidal adverse effects are recommended. Patients should be started on a low dose and closely monitored for adverse effects (Table 2) . For the treatment of psychosis, risperidone has been reported to have the strongest evidence. 32 For treating agitation/ aggression, risperidone and olanzapine have the strongest evidence, while weaker evidence exists for aripiprazole. 28 Olanzapine and quetiapine have been reported to have the best tolerability. 15 The only antipsychotic currently listed on the PBS for BPSD, including psychotic symptoms and agitation, is risperidone. Review of antipsychotic treatment should occur every four to 12 weeks, considering ongoing need and potential for discontinuation. 15 Patients should be assessed regularly for changes in target symptoms and cognition, and these should be recorded. AChEIs may produce some small benefits in BPSD; however, these are unlikely to be clinically significant. 17, 33 Most mood stabilisers have not been trialled as treatments of BPSD, and limited evidence suggests mood stabilisers are ineffective in managing BPSD. 34 Table 2 reports the conditions for prescribing psychotropics in Alzheimer's disease and recommended treatment regimens.
Where severe BPSD places people with dementia or others at risk, referral to specialist services for BPSD management should be made. 15 
Summary
AChEIs or memantine may be trialled in people with Alzheimer's disease, to delay cognitive and functional decline. The choice of pharmacological agents is based on the stage of Alzheimer's disease, tolerability, adverse effect profile, ease of use and cost. BPSD is common in people with Alzheimer's disease and may respond to symptomatic treatment. Dementia Australia can provide information and assistance with other treatments, support services and education (www.dementia.org.au).
